Pancreatic Cancer: Disease and Pipeline Analysis

270 views

Published on

The pancreas is the 10th most common site of new cancers but is the 4th leading cause of cancer death, largely due the difficulties associated with diagnosing the disease in its early stages. As a consequence, over 80% of patients present with regional spread or distant disease at the time of diagnosis (Stage III or Stage IV) and are unsuitable for surgical resection. Survival rates from the disease are among the lowest for any type of cancer with a median survival time of 4-6 months from diagnosis, a 1-year survival rate of 26% and a 5-year survival rate of only 6%. Following curative resection, median survival time increases to between 12 and 19 months.

In a market with few available therapies that exhibit limited effectiveness and a disease class still classified as “rare”, poor survival rates and lack of viable treatment options remain compelling reasons to develop new “Orphan” therapies to address this large unmet need.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
270
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pancreatic Cancer: Disease and Pipeline Analysis

  1. 1. I EW EV PR Pancreatic Cancer: Disease and Pipeline AnalysisInfo@ISRreports.com ©2013 Industry Standard Research www.ISRreports.com
  2. 2. act with confidenceReport OverviewT he pancreas is the 10th most common site of new cancers but is the 4th leading cause of cancer death, largely due the difficulties associated with diagnosing the disease in its early stages. As a consequence, over 80% of patients present with regional spread or distant disease at the time ofdiagnosis (Stage III or Stage IV) and are unsuitable for surgical resection. Survival rates from the disease areamong the lowest for any type of cancer with a median survival time of 4-6 months from diagnosis, a 1-yearsurvival rate of 26% and a 5-year survival rate of only 6%. Following curative resection, median survival timeincreases to between 12 and 19 months.In a market with few available therapies that exhibit limited effectiveness and a disease class still classified as“rare”, poor survival rates and lack of viable treatment options remain compelling reasons to develop new“Orphan” therapies to address this large unmet need. 67 pages 38 charts and graphs Q2 2013 publication date What you will learn in this report: How you can use this report: • Information on over sixty potential new • Optimize your product’s global development therapies in active development and commercial strategies • Incidence rate of pancreatic cancer for each of • Benchmark trial length and number of patients the major and emerging global markets (by Phase) • Drug approval dynamics by country • Identify drug candidates for partnering strategies • Trial and Recruitment environment • Evaluate your pipeline against products • Regulatory environment currently in development • Competitive product landscape • Identify the most effectives market entry • Pricing and reimbursement environment strategiesMajor Sections Valuable for:1. Pancreatic Cancer Overview 1. Brand Managers2. Commercial Rationale 2. Medical Directors3. Environmental Analysis 3. Portfolio Managers4. Clinical Development Pipeline 4. Executive Suite5. Clinical Trial Environment www.ISRreports.com ©2013 | Preview of: Pancreatic Cancer: Disease and Pipeline Analysis 2
  3. 3. act with confidenceTable of Contents Full Table of Contents, list of figures, and list of tables, are available in the report preview, free on our website: http://www.isrreports.com/industry-reports/preview/pancreatic-cancer-disease-and-pipe- line-analysis www.ISRreports.com ©2013 | Preview of: Pancreatic Cancer: Disease and Pipeline Analysis 3
  4. 4. act with confidenceSample Page act with confidence Figure 2. Global Map of per Capita Adult Alcohol Consumption (Pure Alcohol, litres) Source: World Health Organization [3] The association between pancreatic cancer and diet, alcohol consumption and smoking are discussed further in Chapter 3. Orphan Disease Status Due to the relatively low number of people affected by pancreatic cancer it is classified as an orphan or rare disease. This is defined in the US as a disease which affects fewer than 200,000 individuals, in Japan as one which affects less than 50,000 people and in the EU as affecting less than 1 in 2,000 individuals at any given time. Orphan disease status can result in potential therapies for the treatment of pancreatic cancer being eligible for Orphan Drug Designation. This designation allows the developing company to receive tax breaks and market exclusivity on approval of the therapy. In the US, under the terms of the Orphan Drug Act, the new therapy may receive 7 years market exclusivity and is not subject to discounting under the new healthcare law. In addition the therapy is not subject to prescription drug user fee act (PDUFA) fees unless the application includes a non-orphan disease. In addition to favourable market conditions, as the treatment options for the disease are so limited, a single pivotal phase III trial is all that is usually required for the development plan, thereby potentially significantly decreasing drug development costs. www.ISRreports.com ©2013 | Pancreatic Cancer: Disease and Pipeline Analysis 17 www.ISRreports.com ©2013 | Preview of: Pancreatic Cancer: Disease and Pipeline Analysis 4
  5. 5. act with confidenceOrdering Information Ordering information and additional sample pages are available in the full preview, free on our website: http://www.isrreports.com/industry-reports/preview/pancreatic-cancer-disease-and-pipe- line-analysis www.ISRreports.com ©2013 | Preview of: Pancreatic Cancer: Disease and Pipeline Analysis 5

×